Tag archive for ‘Bemarituzumab’
Amgen acquisition of Five Prime Therapeutics
By businessnewstoday On Thursday, March 4th, 2021

Amgen to acquire Five Prime Therapeutics for gastric cancer candidate bemarituzumab

(adsbygoogle = window.adsbygoogle || []).push({}); Amgen acquisition of Five Prime Therapeutics : Amgen has agreed to acquire Five Prime Therapeutics, a clinical-stage biotech company, for about $1.9 More...

By pharmanewsdaily On Monday, October 1st, 2018

Five Prime, Zai Lab initiate phase 3 trial of bemarituzumab chemo combo

Five Prime Therapeutics and Zai Lab have dosed the first patient in a phase 3 study of bemarituzumab (FPA144) in combination with chemotherapy in patients having advanced gastric cancer (GC) or gastroesophageal More...